iRhythm Technologies Inc (IRTC) - Net Assets
Based on the latest financial reports, iRhythm Technologies Inc (IRTC) has net assets worth $152.75 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.02 Billion) and total liabilities ($867.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IRTC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $152.75 Million |
| % of Total Assets | 14.97% |
| Annual Growth Rate | 33.9% |
| 5-Year Change | -45.35% |
| 10-Year Change | 65.02% |
| Growth Volatility | 444.19 |
iRhythm Technologies Inc - Net Assets Trend (2013–2025)
This chart illustrates how iRhythm Technologies Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of iRhythm Technologies Inc for the complete picture of this company's asset base.
Annual Net Assets for iRhythm Technologies Inc (2013–2025)
The table below shows the annual net assets of iRhythm Technologies Inc from 2013 to 2025. For live valuation and market cap data, see IRTC stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $152.75 Million | +68.02% |
| 2024-12-31 | $90.91 Million | -56.73% |
| 2023-12-31 | $210.10 Million | -12.39% |
| 2022-12-31 | $239.81 Million | -14.20% |
| 2021-12-31 | $279.51 Million | -18.18% |
| 2020-12-31 | $341.61 Million | +152.28% |
| 2019-12-31 | $135.41 Million | +148.81% |
| 2018-12-31 | $54.42 Million | -31.59% |
| 2017-12-31 | $79.55 Million | -14.05% |
| 2016-12-31 | $92.56 Million | +191.08% |
| 2015-12-31 | $-101.62 Million | -1499.01% |
| 2014-12-31 | $7.26 Million | +57.91% |
| 2013-12-31 | $4.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to iRhythm Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 73581100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $32.00K | 0.02% |
| Other Comprehensive Income | $403.00K | 0.26% |
| Other Components | $955.76 Million | 625.72% |
| Total Equity | $152.75 Million | 100.00% |
iRhythm Technologies Inc Competitors by Market Cap
The table below lists competitors of iRhythm Technologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BrightGene Bio Medical Technology C
SHG:688166
|
$3.91 Billion |
|
EO Technics Co. Ltd
KQ:039030
|
$3.91 Billion |
|
AUMOVIO N
XETRA:AMV0
|
$3.91 Billion |
|
Tsinghuatongfang Co Ltd
SHG:600100
|
$3.91 Billion |
|
Chongqing Brewery Co Ltd
SHG:600132
|
$3.90 Billion |
|
Federated Investors Inc B
NYSE:FHI
|
$3.89 Billion |
|
Air Canada
TO:AC
|
$3.89 Billion |
|
FLSmidth & Co.
CO:FLS
|
$3.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iRhythm Technologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 90,908,000 to 152,746,000, a change of 61,838,000 (68.0%).
- Net loss of 44,551,000 reduced equity.
- Other comprehensive income increased equity by 238,000.
- Other factors increased equity by 106,151,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-44.55 Million | -29.17% |
| Other Comprehensive Income | $238.00K | +0.16% |
| Other Changes | $106.15 Million | +69.5% |
| Total Change | $- | 68.02% |
Book Value vs Market Value Analysis
This analysis compares iRhythm Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 33.40x to 25.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $3.62 | $120.80 | x |
| 2014-12-31 | $0.49 | $120.80 | x |
| 2015-12-31 | $-6.88 | $120.80 | x |
| 2016-12-31 | $17.51 | $120.80 | x |
| 2017-12-31 | $3.52 | $120.80 | x |
| 2018-12-31 | $2.28 | $120.80 | x |
| 2019-12-31 | $5.36 | $120.80 | x |
| 2020-12-31 | $12.31 | $120.80 | x |
| 2021-12-31 | $9.53 | $120.80 | x |
| 2022-12-31 | $8.02 | $120.80 | x |
| 2023-12-31 | $6.88 | $120.80 | x |
| 2024-12-31 | $2.91 | $120.80 | x |
| 2025-12-31 | $4.77 | $120.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iRhythm Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.96%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 6.68x
- Recent ROE (-29.17%) is above the historical average (-78.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -295.41% | -88.42% | 1.16x | 2.88x | $-14.05 Million |
| 2014 | -217.95% | -72.79% | 1.18x | 2.55x | $-16.56 Million |
| 2015 | 0.00% | -63.09% | 0.95x | 0.00x | $-12.64 Million |
| 2016 | -22.58% | -32.62% | 0.46x | 1.49x | $-30.16 Million |
| 2017 | -37.38% | -30.00% | 0.74x | 1.67x | $-37.70 Million |
| 2018 | -92.57% | -34.21% | 1.23x | 2.20x | $-55.82 Million |
| 2019 | -40.30% | -25.43% | 0.70x | 2.26x | $-68.11 Million |
| 2020 | -12.83% | -16.53% | 0.52x | 1.50x | $-77.99 Million |
| 2021 | -36.26% | -31.40% | 0.70x | 1.66x | $-129.31 Million |
| 2022 | -48.44% | -28.27% | 0.92x | 1.87x | $-140.14 Million |
| 2023 | -58.74% | -25.05% | 1.14x | 2.06x | $-144.42 Million |
| 2024 | -124.62% | -19.14% | 0.64x | 10.25x | $-122.38 Million |
| 2025 | -29.17% | -5.96% | 0.73x | 6.68x | $-59.83 Million |
Industry Comparison
This section compares iRhythm Technologies Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,555,245,291
- Average return on equity (ROE) among peers: -57.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iRhythm Technologies Inc (IRTC) | $152.75 Million | -295.41% | 5.68x | $3.90 Billion |
| Abbott Laboratories (ABT) | $24.08 Billion | 18.37% | 0.83x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $1.47 Billion | -46.29% | 2.07x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $15.99 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.10 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $125.55 Million |
About iRhythm Technologies Inc
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring s… Read more